Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioGaia AB ( ($SE:BIOG.B) ) has provided an announcement.
BioGaia has reported results from a 10-year follow-up study showing that early-life supplementation with its probiotic strain Limosilactobacillus reuteri Protectis is associated with a substantially lower prevalence of functional abdominal pain in children at age ten. The observational study, published in Nutrients and based on 200 participants from an original randomized infant trial, found that only 13.1 percent of children given the probiotic met diagnostic criteria for functional abdominal pain, compared with 80.2 percent in the placebo group, suggesting potentially long-lasting gut health benefits from early microbiome support.
The findings, while not proving causation, reinforce the clinical relevance of BioGaia’s long-term investment in infant probiotics and strengthen its positioning in the pediatric gastrointestinal segment. By indicating that interventions during a critical early developmental window may have durable effects on digestive wellbeing, the study could support broader medical and consumer acceptance of preventive probiotic use in infants and underpin demand for BioGaia’s products among parents, healthcare professionals, and distributors.
The most recent analyst rating on ($SE:BIOG.B) stock is a Hold with a SEK122.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia AB is a Swedish probiotic company focused on microbiome research and the development, manufacturing, marketing, and sale of probiotic products targeting gut, immune, and oral health. Its products are distributed through partners and its own channels in more than 100 markets worldwide, and the company’s class B shares are listed on the Mid Cap segment of Nasdaq Stockholm.
Average Trading Volume: 260,234
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK11.61B
For detailed information about BIOG.B stock, go to TipRanks’ Stock Analysis page.